Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19077885 | 1.00 | CYP17A1 (0.43) | CYP17A1MYCEGLN2NAMPTMAP4K4 | |
| SCHEMBL19065660 | 0.82 | MYC (0.49) | MYCPIK3C3MAPTGSK3B | |
| SCHEMBL2961095 | 0.82 | EGLN2 (0.47) | CYP17A1EGLN2NAMPTMAP4K4ATR | |
| SCHEMBL29529712 | 0.82 | EGLN2 (0.47) | CYP17A1EGLN2NAMPTMAP4K4ATR | |
| SCHEMBL19077874 | 0.80 | CYP17A1 (0.43) | CYP17A1NAMPTMAP4K4PIK3C3ATR | |
| SCHEMBL29675336 | 0.80 | CYP17A1 (0.43) | CYP17A1NAMPTMAP4K4PIK3C3ATR | |
| SCHEMBL20414020 | 0.79 | PTPN11 (0.45) | EGLN2NAMPTPIK3C3 | |
| SCHEMBL13389025 | 0.78 | CYP17A1 (0.47) | CYP17A1NAMPTMAP4K4ATRSREBF2 | |
| SCHEMBL6756707 | 0.77 | NAMPT (0.60) | CYP17A1NAMPTPORCN | |
| SCHEMBL29934130 | 0.76 | NAMPT (0.52) | CYP17A1NAMPTMAP4K4ATRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | CYP17A1 2139/4885MYC 2794/4885EGLN2 4386/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | CYP17A1 2139/4885MYC 2794/4885EGLN2 4386/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | CYP17A1 2139/4885MYC 2794/4885EGLN2 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.